Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Metabolic Syndrome
NCT07065357Phase 3Enrolling by invitation
- Sponsor
- The University of Hong Kong
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in metabolic syndrome (2 arms), sponsored by The University of Hong Kong. Primary endpoint: Change in continuous metabolic syndrome risk score at 6 months. Started Aug 2025; status: enrolling by invitation.
02
Drugs
empagliflozin
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT07065357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065357.